Frontier Medicines Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
112
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$100M
- Investors
-
14
Frontier Medicines General Information
Description
Developer of a chemoproteomics platform designed to accelerate the development of medicines. The company's platform integrates computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery and development, enabling healthcare professionals to provide medicines to patients that redefine the course of debilitating diseases.
Contact Information
Website
www.frontiermeds.comCorporate Office
- 151 Oyster Point Boulevard
- 2nd Floor
- San Francisco, CA 94080
- United States
Corporate Office
- 151 Oyster Point Boulevard
- 2nd Floor
- San Francisco, CA 94080
- United States
Frontier Medicines Timeline
Frontier Medicines Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series C) | 26-Feb-2024 | $100M | Completed | Clinical Trials - Phase 1 | ||
| 4. Early Stage VC (Series B) | 25-Jun-2021 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 01-Aug-2019 | Completed | Pre-Clinical Trials | |||
| 2. Early Stage VC (Series A) | 25-Jun-2019 | $67M | $67M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2018 | Completed | Startup |
Frontier Medicines Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A2 | 26,800,000 | $0.000100 | 6% | $1.25 | $1.25 | 1x | $1.25 | 14.58% |
| Series A1 | 33,500,000 | $0.000100 | 6% | $1 | $1 | 1x | $1 | 18.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Frontier Medicines Comparisons
Industry
Financing
Details
Frontier Medicines Competitors (5)
One of Frontier Medicines’s 5 competitors is Kymera Therapeutics, a Formerly VC-backed company based in Watertown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| C4 Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Dendreon | Formerly VC-backed | Seal Beach, CA | ||||
| Arvinas | Formerly VC-backed | New Haven, CT | ||||
| Nurix Therapeutics | Formerly VC-backed | San Francisco, CA |
Frontier Medicines Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Frontier Medicines Patents
Frontier Medicines Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4476220-A1 | Methods for treatment of cancer | Pending | 07-Feb-2022 | ||
| EP-4426695-A1 | Kras g12c inhibitors | Pending | 05-Nov-2021 | ||
| CA-3236238-A1 | Kras g12c inhibitors | Pending | 05-Nov-2021 | ||
| AU-2022380839-A1 | Kras g12c inhibitors | Pending | 05-Nov-2021 | ||
| US-20250019387-A1 | Kras g12c inhibitors | Pending | 05-Nov-2021 | C07D519/00 |
Frontier Medicines Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Frontier Medicines Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Galapagos (Biotechnology) | Corporation | Minority | ||
| ArrowMark Partners | Asset Manager | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Driehaus Capital Management | Corporation | Minority | ||
| Sphera Funds Management | Hedge Fund | Minority |
Frontier Medicines FAQs
-
When was Frontier Medicines founded?
Frontier Medicines was founded in 2018.
-
Where is Frontier Medicines headquartered?
Frontier Medicines is headquartered in San Francisco, CA.
-
What is the size of Frontier Medicines?
Frontier Medicines has 112 total employees.
-
What industry is Frontier Medicines in?
Frontier Medicines’s primary industry is Drug Discovery.
-
Is Frontier Medicines a private or public company?
Frontier Medicines is a Private company.
-
What is the current valuation of Frontier Medicines?
The current valuation of Frontier Medicines is .
-
What is Frontier Medicines’s current revenue?
The current revenue for Frontier Medicines is .
-
How much funding has Frontier Medicines raised over time?
Frontier Medicines has raised $255M.
-
Who are Frontier Medicines’s investors?
Galapagos (Biotechnology), ArrowMark Partners, Deep Track Capital, Driehaus Capital Management, and Sphera Funds Management are 5 of 14 investors who have invested in Frontier Medicines.
-
Who are Frontier Medicines’s competitors?
Kymera Therapeutics, C4 Therapeutics, Dendreon, Arvinas, and Nurix Therapeutics are competitors of Frontier Medicines.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
